A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations
← catalyst calendarSponsored by Aligos Therapeutics (industry) · ALGS — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
8actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-25 | actual | When the study began enrolling |
| Primary completion | 2025-05-08 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-16 | actual | The whole study's end, after follow-up |
| First posted | 2025-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteer Study
Intervention
- Drug: ALG-055009
Primary outcomes
what the primary-completion date above is the date OFAUC0-24 of ALG-055009 in Plasma
measured 12 days
AUClast of ALG-055009 in Plasma
measured 12 days
AUCinf of ALG-055009 in Plasma
measured 12 days
Tmax of ALG-055009 in Plasma
measured 12 days
Cmax of ALG-055009 in Plasma
measured 12 days
C24 of ALG-055009 in Plasma
measured 12 days
C0 (predose) of ALG-055009 in Plasma
measured 12 days
t½ of ALG-055009 in Plasma
measured 12 days
Permalink · ALGS's whole pipeline · Catalyst calendar · Every registered study · What changed